JPMorgan analyst Chris Schott lowered the firm’s price target on Pfizer to $30 from $34 and keeps a Neutral rating on the shares. While Pfizer shares appear increasingly washed out at current levels, the firm does not see a clear path for the stock to recover given the ongoing uncertainty on the company’s core earnings power.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on PFE:
- Pfizer’s (NYSE:PFE) Disappointing FY24 Guidance Rattles Investors
- Goldman Sachs Says These 3 Healthcare Giants Look Very Attractive Right Now
- M & A News: Pfizer (NYSE:PFE) to Seal $43B Seagen Deal, Analyst Remains Upbeat
- Take-Two to be added to Nasdaq-100 index, Seagen to be removed at open on 12/18
- Pfizer call volume above normal and directionally bullish